|
|
By Anna Rose Welch, chief editor, Biosimilar Development
As an FDA regulator explored in a recent presentation, biopharmaceutical manufacturing innovation has not kept pace with R&D. He shared several thoughts on why this may be the case, offering a call to action for the industry to reevaluate its notions of value to encourage greater manufacturing innovation.
|